Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Colorado: - Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- Intermountain Health Platte Valley Hospital — Brighton, Colorado
- Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Colorado: - UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Colorado: - Research Site — Denver, Colorado
- Research Site — Lone Tree, Colorado
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to o…
Sponsor: Pfizer
NCT ID: NCT07392892
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
Phase 3 Recruiting Industry
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…
Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in Colorado: - Research Site — Aurora, Colorado
Phase 3 Recruiting Industry
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positi…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT06532006
Sites in Colorado: - Banner MD Anderson Cancer Center — Greeley, Colorado
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 2 Recruiting Industry
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06157892
Sites in Colorado: - Colorado West Healthcare System, dba Community Hospital — Grand Junction, Colorado
- Colorado West Healthcare, dba Grand Valley Oncology — Grand Junction, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Colorado: - Rocky Mountain Cancer Centers — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Colorado: - Rocky Mountain Cancer Center — Littleton, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…
Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 2 Recruiting Industry
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibi…
Sponsor: Aadi Bioscience, Inc.
NCT ID: NCT05997056
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT07192432
Sites in Colorado: - SCRI Denver DDU at HealthOne — Denver, Colorado
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Colorado: - University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Colorado: - University of Colorado - Aurora Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapi…
Sponsor: Incyte Corporation
NCT ID: NCT05238922
Sites in Colorado: - Rocky Mountain Cancer Centers-Sky Ridge — Lone Tree, Colorado
Phase 1 Recruiting Industry
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Colorado: - SCRI at HealthOne — Denver, Colorado
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT07021066
Sites in Colorado: - University of Colorado Health — Aurora, Colorado
Phase 1 Recruiting Industry
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Sponsor: I-Mab Biopharma US Limited
NCT ID: NCT04900818
Sites in Colorado: - UCHealth Cancer Care - Anschutz Medical Campus — Aurora, Colorado
Phase 1 Recruiting Industry
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participan…
Sponsor: Genentech, Inc.
NCT ID: NCT05581004
Sites in Colorado: - University Of Colorado — Aurora, Colorado